Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake

AIM: Regorafenib is an oral multikinase inhibitor with clinical efficacy in a range of advanced solid tumours. A population pharmacokinetic (PK) model was developed to evaluate the variability of the PK of regorafenib and its pharmacologically active metabolites M‐2 and M‐5 in solid tumours. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Keunecke, Anne, Hoefman, Sven, Drenth, Henk‐Jan, Zisowsky, Jochen, Cleton, Adriaan, Ploeger, Bart A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688542/
https://www.ncbi.nlm.nih.gov/pubmed/32358822
http://dx.doi.org/10.1111/bcp.14334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688542/
https://www.ncbi.nlm.nih.gov/pubmed/32358822
http://dx.doi.org/10.1111/bcp.14334

Ejemplares similares